In the ongoing battle against ovarian cancer, a formidable challenge has persisted: a subset of these tumors exhibits an uncanny ability to repair their own DNA, rendering conventional chemotherapy treatments markedly less effective. This persistent DNA repair proficiency manifests as a clinical conundrum, with patients often experiencing rapid relapse within six months despite intensive treatment. Historically, overcoming this resistance has eluded oncologists, prompting urgent calls for novel therapeutic approaches that can dismantle the cancer cells’ protective mechanisms.
Emerging from a collaborative effort spearheaded by researchers at The Wistar Institute and Temple University, a novel metabolic pathway has been illuminated, offering a groundbreaking avenue to tackle ovarian cancers that are adept at DNA repair. The collaborative study, published in the prestigious journal Nature, reveals that alpha-ketoglutarate (αKG), a key metabolic intermediate, accumulates in DNA repair proficient ovarian tumors and plays an unexpected but crucial role in facilitating DNA repair. This discovery overturns conventional assumptions focused solely on αKG’s role in demethylation and opens an unprecedented window into metabolic regulation linked to genome maintenance.
The crux of this research hinges on αKG’s capacity to activate an enzyme called TMLHE, previously unassociated with DNA repair mechanisms. TMLHE catalyzes the initial step in the biosynthesis of carnitine, a metabolite widely recognized for its role in energy metabolism by transporting fatty acids into mitochondria. This metabolic axis—αKG to TMLHE to carnitine production—has now been implicated as a pivotal driver of histone acetylation, a modification that relaxes the tight packaging of DNA around histone proteins. This loosening of chromatin structure is essential for the DNA repair machinery to access and mend damaged genomic regions effectively.
Through the innovative application of CRISPR-based screening technology, the research team systematically identified TMLHE as the linchpin enzyme enabling αKG’s influence on DNA repair. This enzyme had been overlooked by the scientific community, which traditionally linked αKG’s functions exclusively to its role as a cofactor for demethylases. The revelation that TMLHE-mediated carnitine synthesis facilitates histone acetylation fundamentally shifts our understanding of metabolic regulation in cancer cells, underscoring a unique acetylation pathway independent of the known methylation pathways governed by αKG.
Carnitine’s newly discovered role transcends its classical function of mitochondrial fatty acid transport. It acts as a molecular courier, shuttling acetyl groups—key metabolic intermediates—out of mitochondria and into the cell nucleus. Within the nucleus, these acetyl groups are deposited onto histones via acetylation, thereby modulating chromatin accessibility. This biochemical maneuver is integral to efficient DNA repair, as it dictates the spatial dynamics of DNA repair complexes. By modulating histone acetylation, carnitine effectively orchestrates the structural environment necessary for repair proteins to rectify DNA lesions inflicted by chemotherapy.
Crucially, inhibition experiments targeting TMLHE or the carnitine biosynthesis pathway demonstrated a pronounced impairment in histone acetylation at critical chromatin sites. This biochemical blockade hinders the assembly of DNA repair machinery, sensitizing cancer cells to DNA-damaging chemotherapeutic agents such as platinum-based drugs. These findings hold significant therapeutic promise, suggesting that dual targeting of metabolic pathways and DNA repair mechanisms can synergistically overcome chemoresistance and improve clinical outcomes in ovarian cancer patients.
The translational potential of these insights was underscored by preclinical studies employing mildronate, a clinically tolerated inhibitor of carnitine synthesis. When administered concomitantly with cisplatin in mouse models, mildronate significantly curtailed tumor growth, whereas either agent alone elicited minimal effects. This combinatorial approach exemplifies a practical strategy to subvert DNA repair proficiency in tumors, advocating for clinical trials assessing carnitine synthesis inhibitors as adjuvants in chemotherapy regimens.
Further supporting the clinical relevance, patient-derived data revealed that elevated TMLHE expression in tumor biopsies correlated strongly with diminished progression-free survival following chemotherapy. Concurrently, higher serum levels of acetylcarnitine at diagnosis independently predicted accelerated disease progression, presenting an opportunity for biomarker-driven patient stratification. These findings hint at the feasibility of utilizing blood-based tests to identify ovarian cancer patients with treatment-resistant phenotypes and to tailor combination therapies accordingly.
The ramifications of this discovery extend far beyond ovarian cancer alone. Given that αKG is a central metabolic regulator and its levels decline with aging, the elucidated pathway offers a profound new lens through which to investigate gene regulation, genomic integrity, and cellular aging processes. Histone acetylation, modulated via αKG-driven carnitine metabolism, emerges as a vital nexus connecting metabolism to the maintenance of DNA stability, with far-reaching implications across cancer biology, stem cell research, and developmental biology.
This paradigm-shifting study was achieved through an exemplary interdisciplinary collaboration, weaving together expertise in metabolomics, biochemistry, molecular biology, and clinical oncology. The integration of advanced mass spectrometry, molecular genetics, and animal modeling facilitated the comprehensive mapping of the αKG-TMLHE-carnitine axis within cellular and patient tumor contexts. This collective effort epitomizes the power of scientific community and cross-institutional partnerships in addressing complex biomedical challenges.
Dr. Katherine Aird, the senior author and co-leader of the Molecular and Cellular Oncogenesis Program at Wistar, reflected on the unexpected nature of the findings: “Everyone in the field expected the focus to be on demethylases, but discovering TMLHE as a key player revealed an unanticipated metabolic mechanism driving DNA repair.” Nathaniel Snyder, co-senior author and expert in cardiovascular discovery at Temple University, emphasized the novelty of this distinct acetylation pathway controlled by αKG, highlighting its essential role in DNA repair—a biological insight hitherto unrecognized.
Collectively, these findings paint a vibrant portrait of metabolic control of epigenetic regulation, unveiling therapeutic vulnerabilities in chemoresistant ovarian cancers. By harnessing the power of metabolic intervention, there is now a tangible pathway to thwart the resilience of these aggressive tumors, offering renewed hope for patients facing limited treatment options. This advancement not only charts a new course in cancer therapy but also enriches our fundamental understanding of the intertwined nature of metabolism, epigenetics, and genome stability in human health and disease.
Subject of Research: Animals
Article Title: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation
News Publication Date: 27-May-2026
Web References:
- Research Article: https://www.nature.com/articles/s41586-026-10584-7
- DOI: http://dx.doi.org/10.1038/s41586-026-10584-7
References:
Apoorva Uboveja et al., “αKG-mediated carnitine synthesis drives DNA repair via histone acetylation,” Nature, 2026.
Image Credits: The Wistar Institute
Keywords: Ovarian cancer, DNA damage responses, alpha-ketoglutarate, carnitine synthesis, histone acetylation, DNA repair, chemotherapy resistance, TMLHE enzyme, metabolic pathways, epigenetics, cancer metabolism, platinum-based chemotherapy
